Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Regulation BioPharmaceutical

Emer Cooke Nominated To Lead EMA

  • News

Executive Summary

The European Medicines Agency has made its choice for a new executive director.

You may also be interested in...



Emer Cooke Prepares To Take Over As Head Of EMA

The change in leadership at the European Medicines Agency comes at a critical time.

Two In Running For Top Job At EMA

A new executive director will be chosen for the European Medicines Agency on 25 June. The agency's management board has two candidates from which to choose.

‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount

Health technology assessment institute NICE has reversed its provisional rejection of Oxlumo for treating the rare disease, primary hyperoxaluria type 1.

Table

View full table

Topics

Tags:
Europe Regulation BioPharmaceutical
Latest Headlines

FDA’s Califf Calls For Return To Large, Simple Trials Without The ‘Useless Stuff’ That Slows Development

‘Stop Fighting Us’ On Inspections, US FDA’s Califf Tells Industry; Foods Modernization Will Bring ‘Big Change’ To Drug Quality Systems

US FDA Program Streamlining COVID-19 Treatment Development Still Working As Emergency Ends

Biogen/Ionis’ Tofersen: US FDA Considering Both Accelerated And Regular Approval In ALS

See All
UsernamePublicRestriction

Register

PS142443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By